Geroscience Is Rewriting the Logic of Disease Prevention

The dominant model of preventive medicine targets diseases individually — one screening, one drug, one risk factor at a time. Geroscience proposes a different architecture: target the biology of aging itself, and delay the onset of multiple diseases simultaneously. The centenarian data is the evidence that this is achievable.

The Number

Thirty percent of centenarians avoid major age-related diseases — including dementia — completely. A further 53% delay onset until at least age 80. The supercentenarian numbers are even more striking: 56% of semi-supercentenarians and nearly 70% of supercentenarians escape major age-related disease. These individuals aren’t just living longer; they’re compressing morbidity toward the very end of life rather than accumulating disease over decades.

The mechanistic question is what separates them from the general population — and whether those mechanisms can be targeted therapeutically.

The Geroscience Framework

Geroscience operates from a different premise than disease-specific medicine. The shared biology underlying cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer includes: mitochondrial dysfunction, chronic low-grade inflammation (inflammaging), cellular senescence, epigenetic drift, and loss of proteostasis. These are not the diseases themselves — they’re the aging processes that make the diseases more likely.

Only 20–30% of lifespan variation is determined by genetics. The remainder is environment, behavior, and the rate at which these aging hallmarks accumulate. That 70–80% malleability is the entire basis for geroscience as a therapeutic target.

The practical implication: an intervention that slows cellular senescence, for example, would reduce risk across heart disease, cancer, and dementia simultaneously — rather than requiring separate protocols for each. This is the efficiency argument for geroscience over disease-specific prevention.

Where the Clinical Evidence Stands

Three compounds have the strongest translational evidence in 2026:

Metformin (TAME Trial): The Targeting Aging with Metformin trial is the landmark test of whether a single compound can delay the onset of multiple age-related diseases simultaneously in a healthy aging population. Observational data on metformin users consistently shows reduced incidence of cancer, cardiovascular disease, and all-cause mortality relative to comparable non-users. TAME is the randomized trial that will determine whether those associations are causal. Results are expected in the late 2020s.

Senolytics (Dasatinib + Quercetin): Senolytic compounds selectively eliminate senescent cells — the “zombie cells” that accumulate with age, stop dividing, and secrete inflammatory signals that damage surrounding tissue. Dasatinib and quercetin in combination reduce senescent cell burden and improve physical function in animal models; early human trials in disease populations (pulmonary fibrosis, diabetic kidney disease) show measurable benefit. Large-scale trials in otherwise healthy aging populations remain in early phases.

Rapamycin (mTOR Inhibition): Rapamycin extends lifespan in every model organism tested and delays multiple age-related pathologies in mice. It inhibits mTOR, a cellular growth pathway that becomes chronically overactive with age and contributes to cellular senescence and cancer risk. Human trials in aging populations are earlier-stage than metformin or senolytics, and the immunosuppressive effects at higher doses create clinical complexity for healthy population use.

What This Means for Biomarker Strategy

The geroscience paradigm demands different diagnostics than disease-specific prevention. Waiting for a blood pressure reading to cross a threshold or for a tumor marker to appear is treating aging reactively. The emerging approach tracks:

• Biological age vs. chronological age (epigenetic clocks like GrimAge or PhenoAge)
• Senescent cell burden (p16 expression, inflammatory cytokine panels)
• Mitochondrial function (VO2max, lactate clearance)
• Protein homeostasis markers

These panels identify individuals who are aging faster biologically than their birth year suggests — and theoretically, provide intervention targets before disease emerges. The clinical infrastructure for acting on these markers lags the measurement capability; knowing your biological age is currently more useful for motivation than treatment decisions in most clinical contexts.

The Honest Caveat

The gap between animal model results and human clinical evidence remains wide. Rapamycin extends lifespan in mice reliably and repeatedly; it is not an established human aging intervention. Senolytics produce striking results in specific disease populations; their effect in healthy aging humans is unknown. The TAME trial will be the first properly powered, randomized test of the geroscience hypothesis in a human cohort — its results will either validate the framework or force significant revision.

The supplement market has already priced in assumptions about NAD+ precursors (NMN, NR), resveratrol, and other compounds that precede solid human longevity evidence. Strong mechanistic rationale and animal data exist for several; none have cleared randomized controlled trials for longevity endpoints in humans.

Source: Superpower

Content created with AI assistance and reviewed for accuracy.